Corium Shares Outstanding 2013-2018 | CORI

Corium shares outstanding history from 2013 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Corium shares outstanding for the quarter ending June 30, 2018 were 0.036B, a 15.12% increase year-over-year.
  • Corium 2017 shares outstanding were 0.029B, a 30.46% increase from 2016.
  • Corium 2016 shares outstanding were 0.022B, a 19.1% increase from 2015.
  • Corium 2015 shares outstanding were 0.019B, a 86.27% increase from 2014.
Corium Annual Shares Outstanding
(Millions of Shares)
2017 29
2016 22
2015 19
2014 10
2013 2
2012 2
2011 0
Corium Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 36
Q2 2018 36
Q1 2017 36
Q4 2017 29
Q3 2017 31
Q2 2017 26
Q1 2016 22
Q4 2016 22
Q3 2016 22
Q2 2016 22
Q1 2015 22
Q4 2015 19
Q3 2015 18
Q2 2015 18
Q1 2014 18
Q4 2014 10
Q3 2014 18
Q2 2014 6
Q1 2013 2
Q4 2013 2
Q3 2013 2
Q2 2013 2
Q1 2012 2
Q4 2012 0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.454B $0.032B
Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $64.335B 11.04
Teva Pharmaceutical Industries (TEVA) Israel $21.792B 6.09
Mylan (MYL) United Kingdom $16.606B 7.06
Bausch Health Cos (BHC) Canada $8.483B 6.32
Dr Reddy's Laboratories (RDY) India $5.756B 25.71
Supernus Pharmaceuticals (SUPN) United States $2.517B 26.93
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.287B 3.89
Akorn (AKRX) United States $0.882B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.857B 123.53
Homology Medicines (FIXX) United States $0.747B 0.00
CymaBay Therapeutics (CBAY) United States $0.615B 0.00
Assembly Biosciences (ASMB) United States $0.594B 0.00
Voyager Therapeutics (VYGR) United States $0.498B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.485B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.482B 0.00
Teligent (TLGT) United States $0.185B 0.00
Sol-Gel Technologies (SLGL) Israel $0.125B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.120B 0.00
Aevi Genomic Medicine (GNMX) United States $0.074B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.061B 0.00
Evoke Pharma (EVOK) United States $0.044B 0.00
Acasti Pharma (ACST) Canada $0.037B 0.00
Versartis (ARAV) United States $0.037B 0.00
Agile Therapeutics (AGRX) United States $0.033B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.010B 0.00